✦ LIBER ✦

A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies

✍ Scribed by Leonard Saltz; David Kelsen

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 427 KB
Volume: 66
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19901015)66:8<1688::aid-cncr2820660806>3.0.co;2-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuous infusion 5-fluorouracil with

Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study

✍ Thomas Saphner; Douglass C. Tormey; Mark Albertini 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB 👁 2 views

A phase I trial of dactinomycin intraven

A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 2 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

A phase I, II study of high-dose 5-fluor

A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies

✍ Bach Ardalan; Kasi S. Sridhar; Pasquale Benedetto; Stephen Richman; Stuart Waldm 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB 👁 2 views

A Phase I trial of h-ras antisense oligo

A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

✍ C. Casey Cunningham; Jon T. Holmlund; Richard S. Geary; T. Jesse Kwoh; Andrew Do 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

A randomized Phase III trial of etoposid

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

✍ Fikri İçli; İsmail Çelik; Faruk Aykan; Aytuǧ Üner; Ahmet Demirkazik; Ahmet Özet; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## BACKGROUND. Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with adv